Table 3.
Association between DM and BMI and covariates
| Variable | HR | 95% CI | p-value | |
|---|---|---|---|---|
| BMI, continuous(kg/m2) | 1.07 | 1.02–1.11 | 0.004 | |
| Gleason Score | ||||
| 7 vs 6 | 2.48 | 1.14–5.36 | 0.220 | |
| 8–10 vs 6 | 3.78 | 1.43–9.96 | 0.007 | |
| T-stage | ||||
| T2 vs T1c | 2.55 | 1.40–4.65 | 0.002 | |
| T3/4 vs T1c | 3.52 | 1.47–8.42 | 0.005 | |
| Log iPSA(ng/mL) | 1.94 | 1.40–2.67 | <0.001 | |
| Age(years) | 1.02 | 0.98–1.05 | 0.322 | |
| ADT Use(yes vs no) | 0.71 | 0.34–1.45 | 0.347 | |
DM, distant metastasis; CSM, cause-specific mortality; OM, overall mortality; BMI, body mass index; HR, hazard ratio; ADT, androgen deprivation therapy; iPSA, pre-treatment prostate specific antigen.